Trade Insmed Inc - INSM CFD

Insmed Company profile

About Insmed Incorporated

Insmed Incorporated is a biopharmaceutical company engaged in providing ARIKAYCE (amikacin liposome inhalation suspension) product, which is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developing for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Insmed Incorporated revenues increased 15% to $188.5M. Net loss increased 48% to $434.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development -other increase of 51% to $254.9M (expense), General and Administrative - other increase of 15% to $206.1M (expense).

Equity composition

Common Stock $.1 Par, 08/11, 500M auth., 24,828,101 issd. Insiders own 1.59%. 6/00, Company formed through a reverse acquisition between Insmed Pharmaceuticals and Celtrix Pharmaceuticals (48,887,307 shares issd.). PO: 10/00, 7.475M shares (5.5M by Co.) @ $11.875 by Robertson Stephens.03/11, 1-for-10 reverse stock split.